Sustained Progress made in 2018 Futura Medical plc (AIM: FUM), the pharmaceutical company developing a portfolio of innovative products for sexual health and pain, based on its proprietary, transdermal DermaSys® … Continue reading “Futura Medical Preliminary Results for the year ended 31 December 2018”
LOS ANGELES, 4 April 2019 – ImaginAb Inc., a clinical stage immuno-oncology imaging company, congratulates Dr. Antoni Ribas, Ph.D., member of its Science Advisory Board, on his selection as President-Elect … Continue reading “AACR Elects ImaginAb Science Advisory Board Member, Dr. Antoni Ribas, as President-Elect at 2019 Annual Meeting”
F2G appoints Dr Patrick Vink as Chairman Brings successful track record of building and growing global businesses MANCHESTER, UK & VIENNA, AUSTRIA – 8 April 2019 – F2G Ltd, the European … Continue reading “F2G appoints Dr Patrick Vink as Chairman”
Apr 5, 2019 Stockholm, Sweden, April 5, 2019 – The nomination committee of Calliditas Therapeutics AB (NASDAQ Stockholm: CALTX) (“Calliditas”) has proposed that Elmar Schnee and Diane Parks be elected … Continue reading “Elmar Schnee and Diane Parks proposed as new board members of Calliditas Therapeutics”
Attendance at key European psychiatry summit underlines commitment to medical community CEO Dr. Jörg-Thomas Dierks to attend psychiatry Congress being held in Warsaw April 5, 2019 Neuraxpharm Group, a leading … Continue reading “Neuraxpharm attends 27th European Congress of Psychiatry”
Neuraxpharm Polska to drive growth in significant market Appoints Wojciech Góra as General Manager Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system … Continue reading “Neuraxpharm Group Announces Expansion in Eastern Europe with the Launch of Neuraxpharm Polska”
Arix’s total interest in Aura increases to £8.5 million from £3.9 million Arix commits $4.5million (£3.4 million[1]) to increase its stake to 7.7% Proceeds to be used to support late … Continue reading “Arix Bioscience plc’s portfolio company Aura completes $40 million Series D financing”
Establishes New Clinical Advisory Board of Leading Oncology Experts Cambridge, UK, 1 April 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative … Continue reading “Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer”
Amsterdam, The Netherlands, March 29, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that at its … Continue reading “Kiadis Pharma Announces Results of Extraordinary General Meeting of Shareholders”
LONDON, 28 March, 2019: Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life … Continue reading “Arix Bioscience plc Annual Results for the year ended 31 December 2018”
Arix Bioscience plc: Board changes LONDON, 28 March 2019: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech … Continue reading “Arix Bioscience plc: Board changes”
First patient dosed with Nuformix cocrystal product Cambridge, UK, 22 March 2019: Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small … Continue reading “Nuformix Commences NXP001 Clinical Trial”
Former F-star CEO joins the Board of Directors. NeoPhore Limited, a cancer immuno-oncology company, today announces the appointment of Dr John Haurum as Non-Executive Director with immediate effect. Dr Haurum … Continue reading “NeoPhore appoints Dr John Haurum as Non-Executive Director”
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 Arix co-leads a $63 million Series B investment in new portfolio company Imara Arix commits … Continue reading “Arix co-leads $63 million Series B investment round for Imara”
Michael Lahn appointed Chief Medical Officer Zoë Johnson appointed Chief Scientific Officer Geneva, Switzerland, 12 March 2019: iOnctura SA, the late stage preclinical immuno-oncology company, announced today the completion of … Continue reading “iOnctura bolsters management team with senior appointments”
Forendo Pharma Successfully Completes Phase 1a Clinical Trial of FOR-6219 for the Treatment of Endometriosis Turku, Finland, March 07 2019: Forendo Pharma, a clinical stage drug development company focusing on … Continue reading “Forendo Pharma Successfully Completes Phase 1a Clinical Trial of FOR-6219 for the Treatment of Endometriosis”
March 6, 2019. Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the appointment of Dan Furrer as Head of … Continue reading “European CNS specialist Neuraxpharm appoints Dan Furrer as Head of Corporate Marketing”
Dirk de Naeyer appointed Chief Operations Officer and Martine Nolan as Head of Quality Assurance, effective March 1, 2019 Amsterdam, The Netherlands, March 5, 2019 – Kiadis Pharma N.V. (“Kiadis … Continue reading “Kiadis Pharma Strengthens Management Team”
Geneva, Switzerland, 28th February 2019: iOnctura SA, a late stage preclinical immuno-oncology company, announced today that its abstract (abstract # 1781) entitled “Preclinical development of a novel, highly selective PI3Kδ … Continue reading “iOnctura selected for an oral presentation at 2019 AACR Annual Meeting”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2019 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com